Vycellix’s Collaborating Scientists, comprised of key opinion leaders in their respective fields, are tasked with supporting IND-enabling studies to most rapidly advance Vycellix’s products to the clinic:
Samir El Andaloussi, Ph.D.
Associate Professor in Biomolecular Medicine & Group Leader at Karolinska Institutet, Stockholm, Sweden. Dr. El Andaloussi’s research is focused on exosome-based vehicles for macromolecular drug delivery, and he is a co-founder of Evox Therapeutics.
Karl-Johan Malmberg, M.D., Ph.D.
Professor, Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital and Co-director of NextGenNK, an international Competence Center for the development of next generation NK cell-based cancer immunotherapies based at Karolinska Institutet, Stockholm, Sweden. Dr. Malmberg leads research teams focused on the molecular and cellular basis for NK cell differentiation and repertoire formation in health and disease, and he serves on the Scientific Advisory Boards for Vycellix and Fate Therapeutics.
Jeffrey S. Miller, M.D.
Professor of Medicine at the University of Minnesota and the Deputy Director of the University of Minnesota Masonic Comprehensive Cancer Center. Dr. Miller has more than 20 years of experience studying the biology of NK cells and other immune effector cells and their use in clinical immunotherapy, has more than 200 peer-reviewed publications, serves on the editorial board for Blood, and is a reviewer for a number of journals and NIH grants. In 2015, he was awarded an Outstanding Investigator Award by the U.S. National Cancer Institute.
Björn Önfelt, Ph.D.
Professor of Applied Physics and Research Group Leader at the Science for Life Laboratory at KTH Royal Institute of Technology, Sweden and Professor & Research Group Leader at Karolinska Institutet, Sweden. Dr. Önfelt’s teams are contributing significant understandings for the functions of immune cells, in particular natural killer (NK) cells and T cells and how to translate into efficient immunotherapy.
